Last reviewed · How we verify
2025 Pharmaceutical Patent Cliff
28 drugs
64 patents
11 therapeutic areas
Historical
Sponsors most affected (10)
- Pfizer · 5 drugs
- Boehringer Ingelheim · 2 drugs
- Merck & Co. · 2 drugs
- Novo Nordisk · 2 drugs
- Arbor Pharms Ireland · 1 drug
- University Hospital Birmingham · 1 drug
- Unknown · 1 drug
- Shionogi · 1 drug
- Mayne Pharma · 1 drug
- AstraZeneca · 1 drug
By therapeutic area
Metabolic (7)
- — Zuragard · isopropanol
- — Cuvposa · Shionogi · Anticholinergic
- — Byetta · AstraZeneca · GLP-1 Receptor Agonist [EPC]
- — Tradjenta · Boehringer Ingelheim · Dipeptidyl Peptidase 4 Inhibitor [EPC]
- — Vantobra · Pfizer · tobramycin
- — Victoza · Novo Nordisk · GLP-1 Receptor Agonist [EPC] ·
Formulation - — Ozempic · Novo Nordisk · GLP-1 Receptor Agonist [EPC]
Oncology (5)
- — Taxol · Pfizer · Microtubule Inhibitor
- — Camptosar · Pfizer · Topoisomerase Inhibitor
- — Lymphoseek Kit · Navidea Biopharms · Radioactive Diagnostic Agent
- — Afinitor · Novartis · Kinase Inhibitor [EPC] ·
Method of Use - — Jevtana Kit · Accord Hlthcare · Microtubule Inhibitor ·
Compound
Cardiovascular (4)
- — Edarbi · Arbor Pharms Ireland · Angiotensin 2 Receptor Blocker
- — Combipres · University Hospital Birmingham · Thiazide-like Diuretic
- — Proventil · Merck & Co. · beta2-Adrenergic Agonist
- — Pradaxa · Boehringer Ingelheim · Direct thrombin inhibitor
Immunology (3)
- — Biktarvy · Gilead Sciences · Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
- — Vizamyl · GE HealthCare · Radioactive Diagnostic Agent [EPC]
- — Acetaminophen · Polymedica · acetaminophen
Respiratory (3)
- — Breo Ellipta · Glaxo Grp Ltd · beta2-Adrenergic Agonist
- — Symdeko (Copackaged) · Vertex Pharms
- — Trikafta (Copackaged) · Vertex Pharms Inc
Other (1)
- — Nextstellis · Mayne Pharma · Estrogen
Gastroenterology (1)
- — Pantoprazole Sodium · Pfizer · Proton pump inhibitor (PPI)
Ophthalmology (1)
- — Bupivacaine Hydrochloride · Pfizer · Amide-type local anesthetic
Bone (1)
- — Ortho-Novum 10/11-21 · Merck & Co. · Estrogen
Nephrology (1)
- — Xelstrym · UCB · Central Nervous System Stimulant [EPC]
Neuroscience (1)
- — Lybalvi · Alkermes Inc · Atypical Antipsychotic [EPC]
Subscribe to patent-cliff alerts
Push every new patent expiry into your RSS reader:
Related
- Biosimilar tracker — who's competing for each post-cliff originator
- Patent cliff revenue calculator
- 2025 patent expiries dataset (CSV / JSON)